User profiles for Thomas A. Murray
 | Thomas A MurrayAssistant Professor of Biostatistics, University of Minnesota Verified email at umn.edu Cited by 3015 |
[HTML][HTML] Randomized trial of metformin, ivermectin, and fluvoxamine for Covid-19
…, JL Thompson, DR Boulware, TA Murray - … England Journal of …, 2022 - Mass Medical Soc
Background Early treatment to prevent severe coronavirus disease 2019 (Covid-19) is an
important component of the comprehensive response to the severe acute respiratory …
important component of the comprehensive response to the severe acute respiratory …
[HTML][HTML] Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind …
…, B Patel, G Griffiths, NS Bhat, TA Murray… - The Lancet Infectious …, 2023 - thelancet.com
Background Post-COVID-19 condition (also known as long COVID) is an emerging chronic
illness potentially affecting millions of people. We aimed to evaluate whether outpatient …
illness potentially affecting millions of people. We aimed to evaluate whether outpatient …
Advanced reperfusion strategies for patients with out-of-hospital cardiac arrest and refractory ventricular fibrillation (ARREST): a phase 2, single centre, open-label …
…, G Raveendran, E Walser, J Connett, TA Murray… - The lancet, 2020 - thelancet.com
Background Among patients with out-of-hospital cardiac arrest (OHCA) and ventricular
fibrillation, more than half present with refractory ventricular fibrillation unresponsive to initial …
fibrillation, more than half present with refractory ventricular fibrillation unresponsive to initial …
Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: A randomised, double-blind, phase 3 trial
Background Tixagevimab–cilgavimab is a neutralising monoclonal antibody combination
hypothesised to improve outcomes for patients hospitalised with COVID-19. We aimed to …
hypothesised to improve outcomes for patients hospitalised with COVID-19. We aimed to …
[HTML][HTML] Observational study of metformin and risk of mortality in patients hospitalized with Covid-19
Objective: We sought to identify whether metformin reduced mortality from Covid19 and if
sex specific interactions exist. Design: Retrospective review of de-identified claims from …
sex specific interactions exist. Design: Retrospective review of de-identified claims from …
[HTML][HTML] Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis
Background Type 2 diabetes and obesity, as states of chronic inflammation, are risk factors
for severe COVID-19. Metformin has cytokine-reducing and sex-specific immunomodulatory …
for severe COVID-19. Metformin has cytokine-reducing and sex-specific immunomodulatory …
Efficacy of losartan in hospitalized patients with COVID-19–induced lung injury: a randomized clinical trial
Importance SARS-CoV-2 viral entry may disrupt angiotensin II (AII) homeostasis, contributing
to COVID-19 induced lung injury. AII type 1 receptor blockade mitigates lung injury in …
to COVID-19 induced lung injury. AII type 1 receptor blockade mitigates lung injury in …
[HTML][HTML] METACOHORTS for the study of vascular disease and its contribution to cognitive decline and neurodegeneration: An initiative of the Joint Programme for …
Dementia is a global problem and major target for health care providers. Although up to 45%
of cases are primarily or partly due to cerebrovascular disease, little is known of these …
of cases are primarily or partly due to cerebrovascular disease, little is known of these …
Renin‐angiotensin system inhibitors in patients with COVID‐19: a meta‐analysis of randomized controlled trials led by the international society of hypertension
…, AE Gracia‐Ramos, TA Murray… - Journal of the …, 2022 - Am Heart Assoc
Background Published randomized controlled trials are underpowered for binary clinical
end points to assess the safety and efficacy of renin‐angiotensin system inhibitors (RASi) in …
end points to assess the safety and efficacy of renin‐angiotensin system inhibitors (RASi) in …
[HTML][HTML] A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19
Background The SARS-CoV-2 virus enters cells via Angiotensin-converting enzyme 2 (ACE2),
disrupting the renin-angiotensin-aldosterone axis, potentially contributing to lung injury. …
disrupting the renin-angiotensin-aldosterone axis, potentially contributing to lung injury. …